Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK publishes provisional 2023 dividend dates

24 Nov 2022 15:00

RNS Number : 5143H
GSK PLC
24 November 2022
 

GSK plc

 

GSK publishes provisional dividend dates

 

GSK announces the following dividend dates for 2023:

 

Results

Announcement date

Ex-dividend date

Record date

Last date for DRIP elections

Payable

Q1 2023

Wednesday 26 April 2023

Thursday 18 May 2023

Friday 19 May 2023

Wednesday 21 June 2023

Thursday 13 July 2023

Q2 2023

Wednesday 26 July 2023

Thursday 17 August 2023

Friday 18 August 2023

Wednesday 20 September 2023

Thursday 12 October 2023

Q3 2023

Wednesday 1 November 2023

Thursday 16 November 2023

Friday 17 November 2023

Monday 18 December 2023

Thursday 11 January 2024

Q4 2023

(Final)

Wednesday 31 January 2024

Thursday 22 February 2024

Friday 23 February 2024

Tuesday 19 March 2024

Thursday 11 April 2024

 

These dates are indicative and may be subject to change.

 

 

 

V A Whyte

Company Secretary

 

24 November 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVBKQBKDBDDDDB
Date   Source Headline
1st May 20243:00 pmRNSTotal Voting Rights
1st May 20247:00 amRNS1st Quarter Results
24th Apr 20247:00 amRNSUS FDA accepts new indication filing for Jemperli
19th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20247:05 amRNSGSK announces additional EAGLE-1 results
17th Apr 20247:00 amRNSResults from long-term data relating to Shingrix
16th Apr 20242:11 pmRNSAmendment - Director/PDMR Shareholding
16th Apr 20247:00 amRNSFDA accepts GSK meningitis vaccine candidate file
15th Apr 20243:30 pmRNSDirector/PDMR Shareholding
4th Apr 202412:05 pmRNSReplacement - Total Voting Rights
2nd Apr 20243:00 pmRNSTotal Voting Rights
26th Mar 20243:30 pmRNSDirector/PDMR Shareholding
25th Mar 20241:00 pmRNSNotice of AGM
22nd Mar 20244:20 pmRNSTransfer of Treasury Shares
22nd Mar 20243:36 pmRNSDirector/PDMR Shareholding
18th Mar 20249:30 amRNSNew Phase III Jemperli data in endometrial cancer
13th Mar 20243:48 pmRNSDirector/PDMR Shareholding
8th Mar 20245:12 pmRNSBoard Committee Change
7th Mar 20247:00 amRNSGSK announces positive Blenrep DREAMM-8 results
6th Mar 20244:00 pmRNSViiV LAI vs oral SOC data in adherence-challenged
5th Mar 20245:24 pmRNSGSK Annual Report 2023 on Form 20-F
5th Mar 20247:00 amRNSNew ViiV LA formulation potential 4-month dosing
1st Mar 20243:00 pmRNSTotal Voting Rights
1st Mar 202412:15 pmRNSGSK publishes Annual Report 2023
29th Feb 20247:05 amRNSDirectorate Change
29th Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
26th Feb 20243:30 pmRNSDirector/PDMR Shareholding
26th Feb 20247:00 amRNSGSK announces positive EAGLE-1 headline results
22nd Feb 20243:30 pmRNSDirector/PDMR Shareholding
21st Feb 20247:00 amRNSViiV LAI superior to orals in adherence-challenged
20th Feb 20249:01 amRNSJulie Brown - External Appointment
19th Feb 20243:30 pmRNSDirector/PDMR Shareholding
15th Feb 20243:32 pmRNSDirector/PDMR Shareholding
15th Feb 20247:00 amRNSGSK completes acquisition of Aiolos Bio
13th Feb 20244:45 pmRNSDirector/PDMR Shareholding - Replacement
13th Feb 20243:40 pmRNSDirector/PDMR Shareholding
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
13th Feb 20243:30 pmRNSDirector/PDMR Shareholding
6th Feb 20247:10 amRNSFDA accepts Arexvy filing for adults 50-59 at risk
6th Feb 20247:05 amRNSShingrix 18+ at risk China filing review accepted
6th Feb 20247:00 amRNSGSK presents positive DREAMM-7 phase III data
1st Feb 20243:30 pmRNSDirector/PDMR Shareholding
1st Feb 20243:00 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
31st Jan 20247:00 amRNSFinal Results
29th Jan 20247:05 amRNSEMA accepts Arexvy filing for adults 50-59 at risk
29th Jan 20247:00 amRNSEuropean Commission authorises Omjjara in the EU
19th Jan 20243:30 pmRNSDirector/PDMR Shareholding
18th Jan 20245:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.